The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.
about
Maraviroc: a review of its use in HIV infection and beyondMaraviroc: the evidence for its potential in the management of HIVEfficient Use of a Crude Drug/Herb Library Reveals Ephedra Herb As a Specific Antagonist for TH2-Specific Chemokine Receptors CCR3, CCR4, and CCR8Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applicationsAsymmetric allylboration of acyl imines catalyzed by chiral diols.Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model.High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.Recent drug approvals from the US FDA and EMEA: what the future holds.Role of tipranavir in treatment of patients with multidrug-resistant HIVAntiviral drugs specific for coronaviruses in preclinical developmentCCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjectsHIV entry inhibitors and their potential in HIV therapyNovel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanismsThe isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIVAllosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.Simian Immunodeficiency Virus SIVagm Efficiently Utilizes Non-CCR5 Entry Pathways in African Green Monkey Lymphocytes: Potential Role for GPR15 and CXCR6 as Viral Coreceptors.New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonistsA common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsAllosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders.International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Maraviroc in the treatment of HIV infection.Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.Pharmacological modulation of chemokine receptor function.Clinical relevance of target identity and biology: implications for drug discovery and development.The structural role of receptor tyrosine sulfation in chemokine recognition.Designing small molecule CXCR3 antagonists.Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 ActivityPreclinical discovery and development of maraviroc for the treatment of HIV.Development of a Moloney murine leukemia virus-based pseudotype anti-HIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors.Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression.Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.Why should cell biologists study microbial pathogens?Metabolism-guided drug designUpdate on the development of HIV entry inhibitors
P2860
Q26778504-43AC2D78-3A8C-498C-9D49-CB6AF50588DFQ28476655-206FB535-B8C5-456E-9A1E-9345A085C593Q28828873-0A4BE2DE-29F7-49FC-A023-01E51801048AQ30366071-5873C30F-4B09-4707-A2CB-9C3A662E3917Q33306078-0A35790F-96B0-4C19-9F69-BA2B29432925Q33501346-69C0311E-61F7-4986-B755-56D3A0310FA7Q33765623-CBC0235E-BE76-4F57-B7BD-3340DD44264AQ33852391-E6BCF3B4-4191-42AC-B97E-0B8AA8BCF846Q34187649-D8701035-3DEA-42DA-AB70-A58C9262EADBQ34332580-7DB3F36F-CD58-447F-86AB-799D6F599B57Q34473072-5C59476E-D765-44AF-BCAC-22A91418A8B7Q34486811-D82FE5E9-5F31-46CB-87C1-33F4AE1C304FQ34589338-4A070928-F045-4ADE-89B8-82EFEADB32ACQ34595921-75691DF6-F53B-48DD-A289-88CA97869A7BQ34725136-17E00B29-EBBD-4063-81A7-58B1401BF1A8Q34939533-C3DC54DC-CB86-4CA5-904E-07014A249E30Q35312348-52138CBC-F311-46DE-A7B6-7654E4A3B9A8Q35758790-EAE278EC-B200-4D48-AA49-87F7942AE166Q36558253-8CAED5CB-1E27-4E8C-A973-EA93565771E9Q36736843-2E43E9D1-806E-46F0-B0C0-A5C636D65DE6Q36823525-E0ACF330-7789-4AF7-AC4B-09322BF0ED9DQ36827946-730EDB53-A076-4305-B66B-02DF3E815BBEQ37416470-75599646-FF40-487A-BF54-2272245932A2Q37432097-B273E7ED-3639-40E8-97F6-2E9FFD62323BQ37634319-D517E5E9-B1C6-46B2-BD24-BD8FC1BD68BFQ37834097-DDA92C84-7794-44B7-990D-0938FB03391DQ37855900-4B65FEC0-4382-4B2B-AA50-B675032F61F1Q37893687-A340C90D-996C-402C-A61B-A89BA7273762Q38147723-A4340DEE-A311-486F-B7F1-A149165CCCF8Q38151741-1437B01E-B97D-4FCF-A36F-16FFB8D291C6Q39051765-BD67F674-57C9-4F2B-ABF4-C3BF4AFB5548Q39098454-B89F393C-C95F-4CA0-8D11-0489B4D27103Q39158970-F252275F-FDFF-4C12-80A6-0414F6F5C27DQ39556338-FE9EA492-0321-4F2D-9093-993A8581790AQ40255176-68478FFE-6D30-4BCB-A565-7049E6BBFED9Q40346497-56F2B808-0F9F-4C70-AD96-F6A482EC425FQ41963164-65417032-AFBE-46ED-8927-0CE9CE5129D2Q42638371-965FBCB2-8682-4627-8724-CA45EC2FDC6BQ56115898-E3A39903-C167-459F-9357-24C8D234F68DQ58388992-F5FB6126-DDDF-453D-AF0B-49B7D16A3D63
P2860
The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@ast
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@en
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@nl
type
label
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@ast
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@en
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@nl
prefLabel
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@ast
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@en
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@nl
P1476
The discovery of the CCR5 rece ...... ent of HIV infection and AIDS.
@en
P2093
Anthony Wood
Duncan Armour
P304
P356
10.1016/S0079-6468(05)43007-6
P577
2005-01-01T00:00:00Z